Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F19%3A43917263" target="_blank" >RIV/00216208:11120/19:43917263 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1111/bjd.17351" target="_blank" >https://doi.org/10.1111/bjd.17351</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjd.17351" target="_blank" >10.1111/bjd.17351</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial

Popis výsledku v původním jazyce

BACKGROUND: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. OBJECTIVE: To demonstrate the superiority of secukinumab vs. placebo in clearing nail psoriasis as assessed by NAil Psoriasis Severity Index (NAPSI) at Week 16 and over time up to Week 132. Presented here is the Week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. METHODS: TRANSFIGURE is a double-blind, randomized, placebo-controlled study in subjects with moderate to severe plaque and nail psoriasis. RESULTS: The primary objective of this study was met: both doses of secukinumab were superior to placebo at Week 16 (NAPSI improvement of -45.3%, -37.9%, and -10.8%, for secukinumab 300 mg, 150 mg and placebo, respectively, P&lt;0.0001). Significant improvements were seen in patients&apos; quality of life: NAPPA-QOL total score median decrease at Week 16 was 60.9%, 49.9% and 15.8% for secukinumab 300 mg, 150 mg and placebo, respectively (P&lt;0.0001). Improvement in nail psoriasis continued to Week 32: NAPSI % change reached -63.2% and -52.6%, for secukinumab 300 mg and 150 mg, respectively. Skin clearance was significant (PASI 90: 72.5%, 54.0% and 1.7% for secukinumab 300 mg, 150 mg and placebo at Week 16, respectively, P&lt;0.0001) and was sustained to Week 32. The most common adverse events were nasopharyngitis, headache, and upper respiratory tract infections. CONCLUSIONS: Secukinumab demonstrated significant and clinically meaningful efficacy and quality of life improvements for patients with nail psoriasis up to Week 32.

Název v anglickém jazyce

Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial

Popis výsledku anglicky

BACKGROUND: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. OBJECTIVE: To demonstrate the superiority of secukinumab vs. placebo in clearing nail psoriasis as assessed by NAil Psoriasis Severity Index (NAPSI) at Week 16 and over time up to Week 132. Presented here is the Week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. METHODS: TRANSFIGURE is a double-blind, randomized, placebo-controlled study in subjects with moderate to severe plaque and nail psoriasis. RESULTS: The primary objective of this study was met: both doses of secukinumab were superior to placebo at Week 16 (NAPSI improvement of -45.3%, -37.9%, and -10.8%, for secukinumab 300 mg, 150 mg and placebo, respectively, P&lt;0.0001). Significant improvements were seen in patients&apos; quality of life: NAPPA-QOL total score median decrease at Week 16 was 60.9%, 49.9% and 15.8% for secukinumab 300 mg, 150 mg and placebo, respectively (P&lt;0.0001). Improvement in nail psoriasis continued to Week 32: NAPSI % change reached -63.2% and -52.6%, for secukinumab 300 mg and 150 mg, respectively. Skin clearance was significant (PASI 90: 72.5%, 54.0% and 1.7% for secukinumab 300 mg, 150 mg and placebo at Week 16, respectively, P&lt;0.0001) and was sustained to Week 32. The most common adverse events were nasopharyngitis, headache, and upper respiratory tract infections. CONCLUSIONS: Secukinumab demonstrated significant and clinically meaningful efficacy and quality of life improvements for patients with nail psoriasis up to Week 32.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Dermatology

ISSN

0007-0963

e-ISSN

—

Svazek periodika

181

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

13

Strana od-do

954-966

Kód UT WoS článku

000493737200016

EID výsledku v databázi Scopus

2-s2.0-85060149116